Expression of bcl-2 but not Bax or p53 correlates with in vitro resistance to a series of anticancer drugs in breast carcinoma

Breast Cancer Research and Treatment

Volumn 61, Issue 3, 2000, Pages 211-216

  Yang, Qi Feng ^a   Sakurai, Takeo ^a   Yoshimura, Goro ^a   Shan, Liang ^a   Suzuma, Takaomi ^a   Tamaki, Takeshi ^a   Umemura, Teiji ^a   Kokawa, Yozo ^a   Nakamura, Yasushi ^a   Nakamura, Misa ^a   Tang, Weihua ^a   Utsunomiya, Hirotoshi ^a   Mori, Ichiro ^a   Kakudo, Kennichi ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Bcl 2; Breast cancer; Chemosensitivity; HDRA

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; MITOMYCIN C; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

APOPTOSIS; ARTICLE; ASSAY; BREAST CARCINOMA; CANCER CELL; CELL KILLING; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE CULTURE;

ANTINEOPLASTIC AGENTS; BCL-2-ASSOCIATED X PROTEIN; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; STATISTICS, NONPARAMETRIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033853548     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006474307180     Document Type: Article

References (29)

1. Breast cancer
2. The genetics of programmed (apoptotic) cell death
3. Drug-target interactions: Only the first step in the commitment to a programmed cell death
4. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthemia
5. Apoptosis, Biochemical events and relevance to enhancer chemotherapy
6. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
7. Bcl-2: Prevention of apoptosis and a mechanism of drug resistance
8. The t(14; 18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining
9. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death
10. Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA
11. Bcl-2 and the regulation of programmed cell death
12. P53 mutations in human cancers
13. The p53 tumor suppressor gene
14. Control of programmed cell death in normal and leukemic cells: New implications for therapy
15. Genetic basis for p53 overexpression in human breast cancer
16. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assay
17. High in vitro-in vivo correlation of drug response using sponge-gel supported three-dimensional histoculture and the MTT endpoint
18. Clinical applications of the histoculture drug response assay
19. Expression of Bcl-2, but not Bax, correlates with estrogen receptor status and tumor proliferation in invasive breast carcinoma
20. Unknotting the complexities of multidrug resistance: The involvement of DNA topoisomerases in drug action and resistance
21. Glutathione-associated enzymes in anticancer drug resistance
22. Clinical multidrug resistance in cancer: A multi-factorial problem
23. Apoptosis in tumorigenesis and cancer therapy
24. Bcl-2 family proteins: Regulators of cell death involved in the pathogenesis of cancer and resistance to therapy
25. Expression of Bax in relation to Bcl-2 and other predictive parameters in breast cancer
26. Reduced expression of the proapoptotic gene BAX is associated with poor response rates to combined chemotherapy and shortened survival in women with metastatic breast carcinoma
27. Immunohistochemical localization of Bcl-2 and Bax proteins in in situ and invasive breast carcinomas
28. Overexpression of the Bcl-2 protein increases the half-life of p21 (Bax)
29. The Bcl-2 protein family: Arbiters of cell survival